MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
OPHC
OptimumBank Holdings, Inc.
There isn't enough reported data to score OPHC yet.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
OPHC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| N/A | |
| N/A |
OPHC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like OPHC.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
OPHC PE Valuation
OPHC has no meaningful PE right now: it lost money over the past year.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
OPHC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OPHC, with profitability improving.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the stronger earnings trend. Trailing diluted EPS is up 29% for MS versus OPHC down 13%.
OPHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.28 | +11% |
| Q3 2025 | $1.15 | -13% |
| Q2 2025 | $1.29 | +9.3% |
| Q1 2025 | $1.34 | +31% |
| Q4 2024 | $1.33 | +53% |
| Q3 2024 | $1.32 | +69% |
| Q2 2024 | $1.18 | +66% |
| Q1 2024 | $1.02 | +48% |
| Q4 2023 | $0.87 | +24% |
OPHC's earnings per share have fallen from their peak: $1.15 over the past year, against $1.69 in mid-2022.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
OPHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $17.2M | +42% |
| Q1 2026 | $15M | +41% |
| Q4 2025 | $13.6M | +32% |
| Q3 2025 | $13M | +29% |
| Q2 2025 | $12.1M | +21% |
| Q1 2025 | $10.7M | +19% |
| Q4 2024 | $10.3M | +26% |
| Q3 2024 | $10.1M | +48% |
OPHC has the edge over MS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 51% | +11 points |
| Q1 2026 | 41% | -7.4 points |
| Q4 2025 | 47% | -4.1 points |
| Q3 2025 | 43% | -0.5 points |
| Q2 2025 | 40% | -6.7 points |
| Q1 2025 | 49% | +13 points |
| Q4 2024 | 52% | +9.7 points |
| Q3 2024 | 44% | +19 points |
OPHC has the edge over MS on profitability, with a higher operating margin.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
OPHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $9.8M | +67% |
| Q1 2026 | $7.4M | +161% |
| Q4 2025 | $6.3M | +10% |
| Q3 2025 | $1.9M | -50% |
| Q2 2025 | $5.9M | +114% |
| Q1 2025 | $2.9M | +25% |
| Q4 2024 | $5.7M | +3487% |
| Q3 2024 | $3.9M | +263% |
OPHC has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over OPHC on shareholder dilution, with a more favorable share count trend.
OPHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +102K shares |
| 1 year | +94% | +11.5M shares |
| 3 years | +298% | +17.7M shares |
| 5 years | +703% | +20.7M shares |
| Available history | +1129% | +21.8M shares |
OPHC has 24M diluted shares, up 94% from a year ago.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
OPHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 3.6x | Elevated |
| Q1 2026 | 4.3x | High |
| Q4 2025 | 5.0x | High |
| Q3 2025 | 3.0x | Moderate |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 3.7x | Elevated |
| Q3 2024 | -1.0x | Net Cash |
OPHC has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
OPHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.0 | Neutral |
| Stochastic | 43.0 | Neutral |
OPHC's weekly RSI is 64 (neutral) and its Stochastic is 43 (neutral).
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
OPHC PE vs Financial Services Sector
| Metric | OPHC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
OPHC has no meaningful PE right now: it lost money over the past year.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
OPHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.86 | 1.1% above |
| 20 week MA | $8.35 | 7.3% above |
| 50 week MA | $6.40 | 40% above |
| 100 week MA | $5.38 | 67% above |
| 200 week MA | $4.65 | 93% above |
OPHC has the edge over MS on trend strength, trading above more of its moving averages.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.
OPHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.86 | $3.28 | +15% |
| 2021 | $3.28 | $4.42 | +35% |
| 2022 | $4.42 | $4.22 | -4.5% |
| 2023 | $4.22 | $4.18 | -0.9% |
| 2024 | $4.18 | $4.74 | +13% |
| 2025 | $4.74 | $4.24 | -11% |
| 2026 YTD | $4.24 | $8.96 | +111% |
OPHC has the edge over MS on returns for 2026, with the stronger performance.